መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › Oregon

በOregon ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 16 ጥናቶች በOregon ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በOregon ውስጥ ያሉ ከተሞች

Official study text (English)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Saint Alphonsus Cancer Care Center-Baker City, Baker City
Saint Alphonsus Cancer Care Center-Ontario, Ontario
Providence Portland Medical Center, Portland
እና 1 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Saint Alphonsus Cancer Care Center-Baker City, Baker City
Saint Charles Health System, Bend
Clackamas Radiation Oncology Center, Clackamas
እና 7 ተጨማሪ

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ

እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Saint Charles Health System, Bend
Saint Alphonsus Cancer Care Center-Ontario, Ontario
Providence Portland Medical Center, Portland
እና 1 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06943872

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07277231

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06846671

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Oregon Health and Science University ( Site 5425), Portland

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT05947851

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

OHSU Knight Cancer Institute, Portland

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT06784167

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, Portland

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06564038

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Oncology Associates of Oregon, Eugene

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07520006

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Oregon Health & Science University, Portland

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ ከ13 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06533579

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Williamette Valley Cancer Institute & Research Center, Eugene

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ሜይ 2026 · NCT06588478

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ኤፕሪ 2026 · NCT06428019

Study of SGR-1505 in Mature B-Cell Neoplasms

Oregon Health and Science University - Knight Cancer Institute, Portland

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ፌብሩ 2026 · NCT05544019

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute, Portland

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ኖቬም 2025 · NCT05943496

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Oregon Health & Science University, Portland

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2025 · NCT05780034

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።